Skip to main content

Table 1 Background characteristics of patients treated with SCIG push

From: Delivery of subcutaneous immunoglobulin by rapid “push” infusion for primary immunodeficiency patients in Manitoba: a retrospective review

 

IVIG naïve (N = 27)

IVIG prior (N = 35)

Age at SCIG initiation, mean (range)

50 (30–78)

51 (26–80)

SCIG dose [g/kg/week] (range)

0.14 (0.06–0.29)

0.15 (0.09–0.22)

Sex

 Female

17 (63%)

23 (66%)

Diagnosis

 CVID

13 (48%)

11 (31%)

 IgGSD

8 (30%)

13 (37%)

 Hypogammaglobulinemia NOS

5 (19%)

7 (20%)

 SAD

1 (3%)

 X-linked agammaglobulinemia

1 (3%)

 Unspecified humoral immunodeficiency

1 (4%)

2 (6%)

Comorbidities

 Bronchiectasis, CRS, or both

15 (56%)

16 (46%)

  1. IGGSD IgG subclass deficiency, CVID common variable immunodeficiency, SAD specific antibody deficiency, NOS Not otherwise specified, CRS chronic rhinosinusitis, g  grams, kg kilograms